四創電子(600990.SH)完成向三十八所轉讓四創科研中心不動產
格隆匯4月2日丨四創電子(600990.SH)公佈,公司於2020年11月12日召開了第六屆董事會第二十九次會議,審議通過了《關於公司向中國電子科技集團公司第三十八研究所轉讓不動產暨關聯交易的議案》,同意將公司位於安徽省合肥市高新區香樟大道199號的四創科研中心不動產,按評估價9939.62萬元作為轉讓價格,轉讓給中國電子科技集團公司第三十八研究所(以下簡稱“三十八所”)。
上述不動產轉讓事項已經公司控股股東(中電博微電子科技有限公司)及實際控制人(中國電子科技集團有限公司)按程序審批,並於近日完成了標的資產的過户登記手續,三十八所已取得上述資產的不動產權證。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.